Based on a novel technology, VacciGuard is developing both effective vaccines against several pathogens for which there is currently no effective vaccine solution, and therapeutic vaccines against devastating diseases, such as cancer.
Infectious diseases are responsible for a third of all deaths worldwide, killing at least 15 million people annually. On top of this high death toll, infectious diseases significantly disable millions more. Lung cancer is the third most common cancer and the most common cause of cancer-related deaths.
VacciGuard was founded in 2007 within the Misgav Venture Accelerator. The Company's R&D is based on a technology platform developed by Prof. Irun Cohen of the Weizmann Institute of Science.
Proof-of-concept has been demonstrated with five different pathogens in relevant animal models.
The Company is currently engaged in the completion of the pharmacological testing of its lung cancer therapeutic vaccine.